A comparison of letrozole and anastrozole followed by letrozole in breast cancer patients

机译：来曲唑和阿那曲唑接着来曲唑在乳腺癌患者中的比较

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundWe previously studied the noninferiority of anastrozole (ANZ) versus ANZ followed by letrozole (A-LTZ) due to reimbursement policy. We found that patients with A-LTZ had better overall survival (OS) than did patients with ANZ alone. This study aimed to prove that patients with A-LTZ also had better OS than patients with letrozole (LTZ) alone.

机译：背景我们之前曾根据报销政策研究过阿那曲唑（ANZ）与ANZ继以来曲唑（A-LTZ）的非劣效性。我们发现，A-LTZ患者比单独的ANZ患者具有更好的总体生存率（OS）。这项研究旨在证明A-LTZ患者比单独使用来曲唑（LTZ）的患者具有更好的OS。

著录项

期刊名称 Breast Cancer : Targets and Therapy
作者
Potchavit Aphinives; Damnern Vachirodom; Chaiyut Thanapaisal; Dhanes Rangsrikajee; Ongart Somintara;
展开▼
作者单位

展开▼
年(卷),期 2015(7),-1
年度 2015
页码 37–41
总页数 5
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词
estrogen receptor-positive hormonal responsive tamoxifen;

机译：雌激素受体阳性;激素反应;他莫昔芬;

相似文献

外文文献
中文文献
专利

1. A comparison of letrozole and anastrozole followed by letrozole in breast cancer patients [J] . Potchavit Aphinives, Damnern Vachirodom, Chaiyut Thanapaisal, Breast Cancer: Targets and Therapy . 2015,第1期

机译：来曲唑和阿那曲唑接着来曲唑在乳腺癌患者中的比较
2. Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial (vol 35, pg 1041, 2017) [J] . Burris Howard A. Journal of Clinical Oncology . 2019,第4期

机译：佐剂Letrozole对蛋白质受体患者阳性阳性阳性，节点阳性早期乳腺癌患者的比较疗效和安全性：随机阶段III女性的最终结果与Anstrozole临床评价（Face）试验（Vol 35，PG 1041,2017）
3. Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial [J] . Smith Ian, Yardley Denise, Burris Howard, Journal of Clinical Oncology . 2017,第10期

机译：佐剂Letrozole对蛋白质激素受体阳性患者患者的辅助Letrozole对Zastrozole的比较疗效和安全性，节点阳性早期乳腺癌：随机阶段III女性的最终结果与Anstrozole临床评价（Face）试验
4. Comparison of Breast Parenchymal Pattern on Prior Mammograms of Breast Cancer Patients and Normal Subjects [C] . Jun Wei, Heang-Ping Chan, Chuan Zhou, SPIE Conference on Medical imaging . 2009

机译：乳腺实质图案对乳腺癌患者和正常科目的先前乳房图谱的比较
5. A Novel Phytoalexin, Glyceollins, Triggers Anti-Proliferative and Apoptotic Effects in Letrozole Resistant T47d Breast Cancer Cells [D] . Walker, Rashidra R. 2020

机译：一种新的植物碱，Glyceollins，触发抗增殖和凋亡作用在Letrozole抗性T47D乳腺癌细胞中
6. Randomized Phase II Neoadjuvant Comparison Between Letrozole Anastrozole and Exemestane for Postmenopausal Women With Estrogen Receptor–Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype—ACOSOG Z1031 [O] . Matthew J. Ellis, Vera J. Suman, Jeremy Hoog, -1

机译：来曲唑阿那曲唑和依西美坦在雌激素受体丰富的第2至3期乳腺癌绝经后妇女中进行的随机II期新辅助治疗比较：基于基线PAM50的固有亚型ACOSOG Z1031的临床和生物标志物结果及预测价值
7. PCN97 A COST-UTILITY ANALYSIS ON THE USE OF TRASTUZUMAB + ANASTROZOLE COMPARED TO LAPATINIB + LETROZOLE, LETROZOLE MONOTHERAPY OR ANASTROZOLE MONOTHERAPY IN THE TREATMENT OF HER2+/HORMONE RECEPTOR POSITIVE (HR+) METASTATIC BREAST CANCER (MBC) FROM THE PERSPECTIVE OF THE UK NATIONAL HEALTH SERVICE (NHS) [O] . McNamara S, Moore L, Ray J 2010

机译：PCN97成本效益分析：使用曲妥珠单抗+纳曲唑与拉帕替尼+左唑，左雷唑单药治疗或阿那曲唑单药疗法治疗HER2 + /激素受体阳性（HR +）转移性肝癌转移服务（NHS）

A comparison of letrozole and anastrozole followed by letrozole in breast cancer patients

摘要

著录项

相似文献

相关主题

期刊订阅